cover image: Paclitaxel drug-eluting stents in peripheral arterial disease

Premium

20.500.12592/32c9tr

Paclitaxel drug-eluting stents in peripheral arterial disease

9 Nov 2015

What is the budget impact of funding Zilver PTX DESs in treating de novo or restenotic lesions in above-the-knee peripheral arterial disease from the perspective of the Ontario Ministry of Health and Long-Term Care? [...] In November 2014, the Canadian Agency for Drugs and Technologies in Health published a brief report on the Zilver PTX DES for the treatment of PAD of the femoropopliteal vessels in Issues in Emerging Health Technologies. [...] Comparison of Zilver PTX DESs With PTA In the primary randomization of the Zilver PTX RCT, the clinical benefit index at 12 months was significantly higher in the DES group (88.3%) than in the PTA group (75.8%) (P < 0.001).
peripheral vascular diseases drug-eluting stents
ISBN
9781460668986
Pages
62
Published in
Ottawa, Ontario